What type of study is this?

September 16, 2025

Supplementary Figure S7 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study

Key Points

Tumor mutational burden (TMB) distinguishes responders from non-responders to ipilimumab and nivolumab.
In ipilimumab-high cohorts, TMB was observed to vary significantly between responders and non-responders.
Observational analysis showed distinct TMB patterns for patients in both ipilimumab-high and ipilimumab-low cohorts.
These findings highlight the potential role of TMB in predicting treatment outcomes for urothelial cancer.

Abstract

Tumor mutational burden (TMB) in responders vs non-responders for ipilimumab-high and ipilimumab-low. Baseline TMB (somatic non-synonymous TMB per Mb) in the ipilimumab-high cohorts (cohort 1 and 2A; left panel) and the ipilimumab-low cohort (cohort 2B; right panel) for responders (blue;

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Chantal F. Stockem

Alberto Gil-Jimenez

Hamza Ali

Actions

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Supplementary Figure S7 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Actions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study

Also consider